ID   17480
AC   CVCL_WZ08
DR   cancercelllines; CVCL_WZ08
DR   Wikidata; Q93300070
RX   PubMed=31150822;
CC   Sequence variation: Mutation; HGNC; HGNC:1101; BRCA2; Simple; p.Lys3326Ter (c.9976A>T) (10204A>T); ClinVar=VCV000038266; Zygosity=Unspecified (PubMed=31150822).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Unspecified (PubMed=31150822).
CC   Omics: Genomics; Whole genome sequencing; Low read coverage.
CC   Omics: Transcriptomics; RNAseq.
CC   Miscellaneous: Age at sampling from personal communication of Castillo-Tong, Dan Cacsire.
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
ST   Source(s): PubMed=31150822
ST   Amelogenin: X
ST   CSF1PO: 10
ST   D12S391: 17,23
ST   D13S317: 10
ST   D16S539: 11
ST   D18S51: 16,18
ST   D19S433: 13,14
ST   D1S1656: 13,15.3
ST   D21S11: 28
ST   D2S1338: 16,17
ST   D3S1358: 14
ST   D5S818: 11
ST   D6S1043: 11,17
ST   D7S820: 11
ST   D8S1179: 14,15
ST   FGA: 24
ST   Penta D: 13,14
ST   Penta E: 12
ST   TH01: 9
ST   TPOX: 8,11
ST   vWA: 17,19
DI   NCIt; C105555; High grade ovarian serous adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_WZ09 ! 8715
OI   CVCL_WZ10 ! 8716
SX   Female
AG   63Y
CA   Cancer cell line
DT   Created: 06-09-19; Last updated: 10-04-25; Version: 9
//
RX   PubMed=31150822; DOI=10.1016/j.canlet.2019.05.032;
RA   Kreuzinger C., von der Decken I., Wolf A., Gamperl M., Koller J.,
RA   Karacs J., Pfaffinger S., Bartl T., Reinthaller A., Grimm C.,
RA   Singer C.F., Braicu E.I., Cunnea P., Gourley C., Smeets D., Boeckx B.,
RA   Lambrechts D., Perco P., Horvat R., Berns E.M.J.J., Castillo-Tong D.C.;
RT   "Patient-derived cell line models revealed therapeutic targets and
RT   molecular mechanisms underlying disease progression of high grade
RT   serous ovarian cancer.";
RL   Cancer Lett. 459:1-12(2019).
//